Stock Watch: Lilly, Third-Quarter Earnings And Receding Pandemic Tides
Watch Out For Comparison Deflation
The comparison of a company’s performance during a windfall period, like one with pandemic-related sales, with a more normal period, can be uncomfortable. Even more so if the underlying business has its weaknesses.
You may also be interested in...
Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.